Idiopathic pulmonary fibrosis: From clinical trials to real-life experiences

Research output: Contribution to journalArticle

Abstract

Randomised controlled clinical trials are fundamental in medicine to develop new effective drugs and new therapeutic regimens and are the strength of evidence-based medicine. These studies allow us to avoid the repetition of misleading experiences that have been reported in the past, where drugs or associations were utilised without compelling evidence and ultimately proven to be ineffective. In recent years, randomised clinical trials have been conducted and concluded for many rare diseases, including idiopathic pulmonary fibrosis. However, clinical trials do not always reflect the real-life scenario. Patients selected for clinical trials present fewer comorbidities, they fall between certain age limits, and the severity of their disease is defined; therefore, they do not always reflect the whole of the population affected by a specific disease. These are the reasons why we also need data that mirror real-life experience. The limitations that these kind of studies present are always several and the studies should be interpreted with caution, although they can fill the important gap between efficacy and effectiveness. In this article, we will review the existing clinical data on real-life treatment of idiopathic pulmonary fibrosis.

Original languageEnglish
Pages (from-to)420-427
Number of pages8
JournalEuropean Respiratory Review
Volume24
Issue number137
DOIs
Publication statusPublished - Sep 1 2015

Fingerprint

Idiopathic Pulmonary Fibrosis
Clinical Trials
Randomized Controlled Trials
Evidence-Based Medicine
Rare Diseases
Pharmaceutical Preparations
Comorbidity
Medicine
Therapeutics
Population

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Idiopathic pulmonary fibrosis : From clinical trials to real-life experiences. / Harari, Sergio; Caminati, Antonella.

In: European Respiratory Review, Vol. 24, No. 137, 01.09.2015, p. 420-427.

Research output: Contribution to journalArticle

@article{5296ed0175654cb6b18c117e7898205b,
title = "Idiopathic pulmonary fibrosis: From clinical trials to real-life experiences",
abstract = "Randomised controlled clinical trials are fundamental in medicine to develop new effective drugs and new therapeutic regimens and are the strength of evidence-based medicine. These studies allow us to avoid the repetition of misleading experiences that have been reported in the past, where drugs or associations were utilised without compelling evidence and ultimately proven to be ineffective. In recent years, randomised clinical trials have been conducted and concluded for many rare diseases, including idiopathic pulmonary fibrosis. However, clinical trials do not always reflect the real-life scenario. Patients selected for clinical trials present fewer comorbidities, they fall between certain age limits, and the severity of their disease is defined; therefore, they do not always reflect the whole of the population affected by a specific disease. These are the reasons why we also need data that mirror real-life experience. The limitations that these kind of studies present are always several and the studies should be interpreted with caution, although they can fill the important gap between efficacy and effectiveness. In this article, we will review the existing clinical data on real-life treatment of idiopathic pulmonary fibrosis.",
author = "Sergio Harari and Antonella Caminati",
year = "2015",
month = "9",
day = "1",
doi = "10.1183/16000617.0042-2015",
language = "English",
volume = "24",
pages = "420--427",
journal = "European Respiratory Review",
issn = "0905-9180",
publisher = "European Respiratory Society",
number = "137",

}

TY - JOUR

T1 - Idiopathic pulmonary fibrosis

T2 - From clinical trials to real-life experiences

AU - Harari, Sergio

AU - Caminati, Antonella

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Randomised controlled clinical trials are fundamental in medicine to develop new effective drugs and new therapeutic regimens and are the strength of evidence-based medicine. These studies allow us to avoid the repetition of misleading experiences that have been reported in the past, where drugs or associations were utilised without compelling evidence and ultimately proven to be ineffective. In recent years, randomised clinical trials have been conducted and concluded for many rare diseases, including idiopathic pulmonary fibrosis. However, clinical trials do not always reflect the real-life scenario. Patients selected for clinical trials present fewer comorbidities, they fall between certain age limits, and the severity of their disease is defined; therefore, they do not always reflect the whole of the population affected by a specific disease. These are the reasons why we also need data that mirror real-life experience. The limitations that these kind of studies present are always several and the studies should be interpreted with caution, although they can fill the important gap between efficacy and effectiveness. In this article, we will review the existing clinical data on real-life treatment of idiopathic pulmonary fibrosis.

AB - Randomised controlled clinical trials are fundamental in medicine to develop new effective drugs and new therapeutic regimens and are the strength of evidence-based medicine. These studies allow us to avoid the repetition of misleading experiences that have been reported in the past, where drugs or associations were utilised without compelling evidence and ultimately proven to be ineffective. In recent years, randomised clinical trials have been conducted and concluded for many rare diseases, including idiopathic pulmonary fibrosis. However, clinical trials do not always reflect the real-life scenario. Patients selected for clinical trials present fewer comorbidities, they fall between certain age limits, and the severity of their disease is defined; therefore, they do not always reflect the whole of the population affected by a specific disease. These are the reasons why we also need data that mirror real-life experience. The limitations that these kind of studies present are always several and the studies should be interpreted with caution, although they can fill the important gap between efficacy and effectiveness. In this article, we will review the existing clinical data on real-life treatment of idiopathic pulmonary fibrosis.

UR - http://www.scopus.com/inward/record.url?scp=84940669065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940669065&partnerID=8YFLogxK

U2 - 10.1183/16000617.0042-2015

DO - 10.1183/16000617.0042-2015

M3 - Article

C2 - 26324803

AN - SCOPUS:84940669065

VL - 24

SP - 420

EP - 427

JO - European Respiratory Review

JF - European Respiratory Review

SN - 0905-9180

IS - 137

ER -